Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients

الملخص EN

Trabectedin and ifosfamide are among the few cytostatic agents active in advanced soft tissue sarcomas (STSs).

Trabectedin is most potent against so-called L-sarcomas (leiomyosarcoma and liposarcoma).

The survival gain and cost-effectiveness of these agents in a second-line setting were analysed in the setting of advanced STS after failure of anthracyclines.

A prospective observational trial had previously been performed to assess the use of trabectedin in a Dutch real-world setting.

Data on ifosfamide monotherapy were acquired from previous studies, and an indirect comparison of survival was made.

A state-transition economic model was constructed, in which patients could be in mutually exclusive states of being preprogression, postprogression, or deceased.

The costs and quality-adjusted life years (QALYs) for both treatments were assessed from a Dutch health-care perspective.

Separate analyses for the group of L-sarcomas and non-L-sarcomas were performed.

Trabectedin treatment resulted in a median progression-free survival of 5.2 months for L-sarcoma patients, 2.0 months for non-L-sarcoma patients, and a median overall survival of 11.8 and 6.0 months, respectively.

For L-sarcoma patients, trabectedin offered an increase of 0.368 life years and 0.251 QALYs compared to ifosfamide and €20,082 in additional costs, for an incremental cost-effectiveness ratio (ICER) of €80,000 per QALY gained.

In the non-L-sarcoma patients, trabectedin resulted in 0.413 less life years and 0.266 less QALYs, at the increased cost of €4,698.

The difference in survival between drugs and the acquisition costs of trabectedin were the main influences in these models.

Trabectedin was shown to have antitumour efficacy in advanced L-sarcoma.

From a health economics perspective, the costs per QALY gained compared to ifosfamide monotherapy that may be acceptable, considering what is currently regarded as acceptable in the Netherlands.